Huang, Wei-ChunWei-ChunHuangHsu, Chih-HsinChih-HsinHsuSung, Shih-HsienShih-HsienSungWEN-JENG HSUEHChu, Chun-YuanChun-YuanChuChang, Chih-PingChih-PingChangChiu, Yu-WeiYu-WeiChiuWu, Chun-HsienChun-HsienWuChang, Wei-TingWei-TingChangLin, LinLinLinLin, Shoa-LinShoa-LinLinCheng, Chin-ChangChin-ChangChengYI-JU WUWu, Shu-HaoShu-HaoWuHsieh, Tsu-YiTsu-YiHsiehHSAO-HSUN HSUFu, MorganMorganFuDai, Zen-KongZen-KongDaiPING-HUNG KUOHWANG, JUEY-JENJUEY-JENHWANGCheng, Shu-MengShu-MengChengTSOC pulmonary hypertension committee2019-11-182019-11-182019-03-260929-6646https://scholars.lib.ntu.edu.tw/handle/123456789/431383Pulmonary arterial hypertension (PAH) is characterized as a progressive and sustained increase in pulmonary vascular resistance, which may induce right ventricular failure. In 2014, the Working Group on Pulmonary Hypertension of the Taiwan Society of Cardiology (TSOC) conducted a review of data and developed a guideline for the management of PAH.4 In recent years, several advancements in diagnosis and treatment of PAH has occurred. Therefore, the Working Group on Pulmonary Hypertension of TSOC decided to come up with a focused update that addresses clinically important advances in PAH diagnosis and treatment. This 2018 focused update deals with: (1) the role of echocardiography in PAH; (2) new diagnostic algorithm for the evaluation of PAH; (3) comprehensive prognostic evaluation and risk assessment; (4) treatment goals and follow-up strategy; (5) updated PAH targeted therapy; (6) combination therapy and goal-orientated therapy; (7) updated treatment for PAH associated with congenital heart disease; (8) updated treatment for PAH associated with connective tissue disease; and (9) updated treatment for chronic thromboembolic pulmonary hypertension.enGuideline; Pulmonary arterial hypertension; Pulmonary hypertension[SDGs]SDG3ambrisentan; anticoagulant agent; beraprost; bosentan; calcium channel blocking agent; diuretic agent; endothelin receptor antagonist; guanylate cyclase activator; iloprost; macitentan; phosphodiesterase V inhibitor; prostacyclin; prostacyclin derivative; prostanoid; riociguat; selexipag; sildenafil; tadalafil; treprostinil; algorithm; Article; blood vessel reactivity; chronic thromboembolic pulmonary hypertension; clinical evaluation; combination drug therapy; congenital heart disease; connective tissue disease; Eisenmenger complex; follow up; heart right ventricle failure; human; lung vascular resistance; oxygen therapy; percutaneous transluminal angioplasty; practice guideline; prognostic assessment; pulmonary hypertension; pulmonary veno-occlusive disease; randomized controlled trial (topic); risk assessment; risk factor; screening; systemic lupus erythematosus; systemic sclerosis; Taiwan; transthoracic echocardiography; tricuspid valve regurgitation; venous thromboembolism; cardiology; medical society; pulmonary hypertension; Cardiology; Humans; Practice Guidelines as Topic; Pulmonary Arterial Hypertension; Societies, Medical; Taiwanjournal article10.1016/j.jfma.2018.12.009309262482-s2.0-85063333446https://api.elsevier.com/content/abstract/scopus_id/85063333446